# Thyroid Nodule Biopsy Thresholds

Use ultrasound risk stratification plus nodule size—not size alone—to select thyroid nodules for ultrasound-guided FNA. ACR TI-RADS reduces biopsy recommendations relative to ATA-based approaches; discordant imaging and cytology should prompt repeat sampling, molecular risk stratification, or diagnostic surgery rather than reassurance.

**Clinical question:** Which thyroid nodules should undergo ultrasound-guided FNA, and how should cytology and imaging discordance change management?

Updated: 2026-09-15T22:06:11.667035+00:00

## What matters in practice
- Select nodules for biopsy by ultrasound risk category and size; ultrasound appearance and size jointly determine FNA need. [15][17]
- Under ACR TI-RADS, a TR3 nodule should be considered for FNA only at 2.5 cm or larger. [1]
- Do not routinely pursue further evaluation of thyroid nodules smaller than 1 cm under the 2015 ATA approach; exceptions depend on concerning clinical or ultrasound context. [2][21]
- Use ultrasound-guided FNA as the primary tissue test; it is outpatient, minimally invasive, and the diagnostic standard for thyroid nodules. [11][12][20]
- For Bethesda III/AUS nodules, repeat FNA can resolve cytology in about half of cases and was less costly than molecular-testing-first strategies in one comparative study. [7]
- When a high-suspicion ultrasound pattern conflicts with indeterminate cytology, repeat ultrasound-guided FNA or molecular testing is appropriate; persistent discordance may justify diagnostic resection. [23]

## Use ultrasound risk and size to decide whether to biopsy

Biopsy selection should begin with a structured thyroid ultrasound assessment rather than palpation or diameter alone.

Order a dedicated thyroid ultrasound to characterize each clinically relevant nodule and apply an established sonographic risk-stratification system before FNA. Ultrasound is the imaging method of choice, and both sonographic appearance and size determine whether biopsy is indicated. [15][17][21]

Use ACR TI-RADS when its scoring framework is available because it standardizes ultrasound-based biopsy selection and is associated with fewer recommended biopsies than ATA-based recommendations in a comparative analysis. In that study, the unnecessary-FNA rate was 26.3% with ACR TI-RADS versus 47.4% with ATA criteria; this tradeoff favors avoiding biopsy of low-yield nodules while requiring reliable sonographic categorization. [8][17]

For an ACR TI-RADS TR3 nodule, consider ultrasound-guided FNA only when the maximum diameter is at least 2.5 cm. A TR3 designation carries low malignancy risk, so biopsy below this threshold is generally not supported by the ACR threshold cited here. [1]
- Document the ultrasound risk category and maximum nodule diameter in the FNA order; a size measurement without a risk category does not establish an evidence-based biopsy threshold. [15][17]
- For nodules that do not meet the ultrasound-system threshold, choose surveillance rather than reflex FNA unless another clinical concern changes the risk assessment. [21]
- If the nodule is smaller than 1 cm, routine further evaluation is generally not recommended in the 2015 ATA framework. [2]

*Biopsy-selection principles supported by ultrasound risk stratification. [1][2][15][17][21]*

| Clinical or ultrasound context | Biopsy threshold or action | Decision consequence |
| --- | --- | --- |
| ACR TI-RADS TR3, low-risk nodule | Consider ultrasound-guided FNA at ≥2.5 cm. [1] | Do not biopsy solely because a lower-risk TR3 nodule is present below 2.5 cm. [1] |
| Nodule <1 cm without a stated high-risk exception | Routine further evaluation is not recommended in the 2015 ATA approach. [2] | Avoid automatic FNA of subcentimeter incidental nodules. [2] |
| Nodule does not meet an established ultrasound-system threshold but clinical concern is present | Consider either FNAC or active surveillance. [21] | Make the decision from the combined clinical and ultrasound risk assessment rather than size alone. [21] |
| Ultrasound features indeterminate or suspicious for malignancy | Proceed to FNA when the established ultrasound grading threshold is met. [19][21] | Obtain cytology to direct surveillance, repeat sampling, molecular testing, or surgery. [19][21] |

## Handle subcentimeter nodules and clinical concern without indiscriminate biopsy

The key exception to size-based restraint is a clinical or imaging context that materially raises malignancy concern.

Do not equate a subcentimeter nodule with an automatic FNA indication. The 2015 ATA guidance cited in the literature does not recommend further evaluation for nodules smaller than 1 cm, and TI-RADS has been validated as a malignancy-risk approach even among nodules 1 cm or smaller. [2][15]

When ultrasound grading alone does not meet an FNA threshold but the clinician identifies another reason for concern, choose between FNAC and active surveillance rather than disregarding the discordant concern. This is a risk-based exception, not a mandate to biopsy every small lesion. [21]

Clinical factors historically associated with higher concern include childhood head and neck irradiation and family history of thyroid cancer; an older guidance excerpt describes consideration of ultrasound-guided FNA for nodules larger than 5 mm in such patients but also notes lack of supporting data for that universal approach. Use these factors to intensify ultrasound review and individualized decision-making rather than applying a blanket 5-mm biopsy rule. [14]
- Escalate from surveillance to tissue sampling when ultrasound or clinical concern becomes sufficient under an established grading system. [21]
- Avoid using nodule growth alone as a malignancy diagnosis; increasing size has only modest predictive power for thyroid cancer. [5]
- Assess cervical lymph nodes during the ultrasound examination when cancer is a concern, because FNA is also used to identify nodal metastasis from papillary thyroid cancer. [11]

*Clinical contexts that modify a size-only biopsy decision. [2][5][11][14][21]*

| Context | Interpretation | Next step |
| --- | --- | --- |
| Subcentimeter nodule with no additional stated concern | Routine further evaluation is generally not recommended in the cited 2015 ATA approach. [2] | Do not reflexively perform FNA. [2] |
| Below-threshold ultrasound category plus clinical concern | Ultrasound grading alone may underestimate the overall clinical concern. [21] | Consider FNAC or active surveillance. [21] |
| Prior childhood neck irradiation or thyroid-cancer family history | These are recognized clinical risk factors, but a universal >5-mm FNA approach lacks supporting data in the cited guidance excerpt. [14] | Individualize the decision using current ultrasound appearance and overall risk. [14] |
| Interval enlargement | Size increase has modest predictive power for cancer. [5] | Reassess ultrasound risk features rather than treating growth alone as proof of malignancy. [5][15] |

## Obtain ultrasound-guided FNA when the biopsy threshold is met

Sampling quality determines whether cytology can safely replace diagnostic surgery.

Perform thyroid FNA under ultrasound guidance when biopsy is selected. FNA is described as the gold-standard evaluation for thyroid nodules and detection of nodal metastasis, is usually outpatient, and is minimally invasive and safe. [11][12][20]

Request cytology reported using the Bethesda System because the central output of FNA is malignancy-risk classification, not simply a benign-versus-cancer label. FNA accurately classifies most nodules as benign and a smaller proportion as malignant, but indeterminate results remain common and require a separate management branch. [4][16]

Treat a nondiagnostic specimen as an inadequate decision point, particularly if ultrasound remains suspicious. Nondiagnostic and indeterminate cytology are among the cytologic situations in which repeat FNA, molecular testing, diagnostic hemithyroidectomy, or surveillance may be considered according to the imaging-risk context. [19][22][23]
- Use ultrasound guidance for repeat sampling when the initial FNA is nondiagnostic or discordant with suspicious imaging. [12][23]
- Do not use a benign cytology result as unconditional reassurance when clinical or ultrasound features indicate increased malignancy risk. [19]
- Consider core-needle biopsy as a potential alternative sampling strategy after a prior nondiagnostic FNA when local expertise and the clinical scenario support it. [22]

*Action after thyroid FNA based on the cytology–ultrasound relationship. [16][19][22][23]*

| FNA result or relationship | Risk interpretation | Next action |
| --- | --- | --- |
| Benign cytology with no discordant high-risk clinical or ultrasound finding | Cytology supports nonoperative management. [16][19] | Use ultrasound surveillance rather than immediate surgery. [14][19] |
| Benign or nondiagnostic cytology with increased-risk ultrasound or clinical findings | Cytology may be discordant with the pretest risk. [19] | Consider repeat FNAC, diagnostic hemithyroidectomy, or active surveillance according to the full risk assessment. [19] |
| Nondiagnostic FNA | No definitive cytologic classification is available. [19][22] | Repeat ultrasound-guided FNA; consider core-needle biopsy in selected previously nondiagnostic nodules. [12][22] |
| Malignant or suspicious-for-malignancy cytology | Cytology generally directs definitive surgical management. [16][23] | Refer for thyroid surgery planning; selected papillary cancers or microcarcinomas may be managed with active surveillance. [16][23] |

## Use repeat FNA, molecular testing, and surgery selectively for indeterminate nodules

Indeterminate cytology is a risk-stratification problem; ultrasound pattern determines how aggressively to resolve it.

For Bethesda III atypia of undetermined significance/follicular lesion of undetermined significance, repeat ultrasound-guided FNA is a reasonable first strategy when immediate surgery is not otherwise indicated. In a 2025 comparative study, repeat FNA produced benign cytology in 48.7% and persistent AUS in 35.9% of cases; surgery and malignancy rates did not significantly differ from molecular-testing-first management, while repeat FNA had the lowest diagnostic cost by Medicare reimbursement rates. [7]

Use molecular testing as a risk-stratification adjunct for AUS/FLUS or suspicious-for-follicular-neoplasm cytology when the result will change the decision between surveillance and diagnostic surgery. Molecular testing can estimate malignancy likelihood and identify tumor phenotypes, but no current molecular test definitively diagnoses malignancy in every indeterminate nodule. [9][16][23]

Give ultrasound discordance decisive weight. Among AUS/FLUS nodules in one study, reported malignancy rates were 7.7% for sonographically benign or very-low-risk nodules, 58% for low- or intermediate-suspicion nodules, and 100% for high-suspicion nodules. A high-suspicion ultrasound result with indeterminate cytology should therefore trigger repeat ultrasound-guided FNA or molecular testing and may support diagnostic resection if uncertainty persists. [23]

Do not manage Bethesda III and Bethesda IV as interchangeable categories. Bethesda IV nodules had higher cancer risk than Bethesda III nodules even with a negative molecular test in a reported follow-up cohort; a negative molecular result should be interpreted with the cytology category and ultrasound pattern rather than used as an isolated rule-out test. [18]
- Choose repeat FNA first for Bethesda III when a benign repeat result would permit surveillance and there is no compelling high-suspicion imaging signal. [7][23]
- Choose molecular testing when it will meaningfully alter the patient-specific choice between surveillance and diagnostic lobectomy. [9][16][23]
- Move toward surgical evaluation for malignant or suspicious cytology and for persistently unresolved high-risk imaging–cytology discordance. [16][19][23]

### Choosing a diagnostic strategy after indeterminate cytology

A repeat FNA and molecular testing are alternatives rather than sequential requirements for every Bethesda III lesion. Repeat FNA resolves a substantial fraction of AUS results, whereas molecular testing is most useful when a quantified change in malignancy risk would alter the operative decision. [7][9][16]

Diagnostic hemithyroidectomy is a defined option when cytology remains indeterminate in a nodule with increased-risk ultrasound or clinical features. The procedure is not required merely because an initial specimen is indeterminate; its value is greatest when persistent uncertainty would otherwise leave a clinically consequential cancer risk unresolved. [19][23]
- Persistent AUS after repeat sampling does not establish benignity; integrate the repeat result with ultrasound risk. [7][23]
- A negative molecular test does not erase the higher baseline concern associated with Bethesda IV relative to Bethesda III cytology. [18]

*Management branch for indeterminate thyroid FNA results. [7][9][16][18][19][23]*

| Scenario | Preferred risk-resolution option | What changes the next step |
| --- | --- | --- |
| Bethesda III/AUS without compelling high-suspicion ultrasound findings | Repeat ultrasound-guided FNA is reasonable. [7][23] | A benign repeat FNA supports surveillance; persistent AUS requires renewed risk stratification. [7] |
| Bethesda III/AUS when surgery versus surveillance remains uncertain | Molecular testing can refine malignancy likelihood. [9][16] | Use the result only if it changes the management choice. [9][16] |
| Indeterminate cytology plus high-suspicion ultrasound pattern | Repeat ultrasound-guided FNA or molecular testing; consider diagnostic resection if discordance persists. [23] | High-suspicion sonography substantially increases reported malignancy risk among AUS/FLUS nodules. [23] |
| Bethesda IV with negative molecular testing | Do not assume risk equals Bethesda III. [18] | Interpret residual risk with cytology category and ultrasound findings before selecting surveillance or surgery. [18] |

## Surveil benign nodules by ultrasound and rebiopsy for renewed discordance

A benign result usually prevents surgery, but surveillance intensity should follow ongoing ultrasound and clinical risk.

For benign nodules, periodic ultrasound monitoring is an appropriate nonoperative pathway. Benign nodules generally do not require treatment, and ultrasound surveillance is recommended rather than routine intervention. [14]

Repeat FNA is most defensible when the prior cytology is benign or nondiagnostic but the ultrasound or clinical assessment remains concerning. This escalation is driven by imaging–cytology mismatch, not by the mere existence of a benign nodule. [19][23]

For patients managed with active surveillance, periodic appointments including ultrasound and blood tests are part of the surveillance construct; the duration and frequency should be individualized to patient risk. [21]
- Reassess the ultrasound risk category at follow-up rather than relying on size change alone. [5][15]
- Use persistent suspicious imaging after a benign or nondiagnostic FNA as a trigger for repeat sampling or surgical risk resolution. [19][23]
- Reserve surgery for malignant or suspicious cytology, unresolved high-risk discordance, or a patient-specific decision after indeterminate-risk counseling. [16][19][23]

*Surveillance and escalation after a nonmalignant or unresolved FNA result. [5][14][19][21][23]*

| Follow-up state | Monitoring approach | Escalation trigger |
| --- | --- | --- |
| Benign nodule without discordant risk features | Periodic thyroid ultrasound monitoring. [14] | New concerning clinical or ultrasound findings. [19] |
| Benign cytology but suspicious ultrasound or clinical context | Do not rely on benign cytology alone. [19] | Repeat FNAC, consider diagnostic hemithyroidectomy, or select active surveillance based on risk. [19] |
| Active surveillance pathway | Periodic visits with investigations such as ultrasound and blood tests; individualize frequency. [21] | A change in ultrasound or clinical risk sufficient to warrant FNAC or surgery. [21] |
| Nodule enlargement during follow-up | Reevaluate sonographic pattern because growth alone has modest predictive value. [5] | Biopsy if the established ultrasound-system threshold is met or concern becomes discordant with prior cytology. [19][21] |

## References
1. ACR TI-RADS Classification and Bethesda Scoring of Thyroid Nodules — jamanetwork.com — https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2809293
2. Machine Learning by Ultrasonography for Genetic Risk Stratification — jamanetwork.com — https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2753566
3. Trends in Diagnosis of Noninvasive Follicular Thyroid Neoplasm ... — jamanetwork.com — https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2786748
4. Performance of a Multigene Genomic Classifier in Thyroid Nodules ... — jamanetwork.com — https://jamanetwork.com/journals/jamaoncology/fullarticle/2713846
5. Natural History of Benign Solid and Cystic Thyroid Nodules — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/0003-4819-138-4-200302180-00010
6. The Significance of Nontoxic Thyroid Nodules: Final Report of a 15 ... — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/0003-4819-69-3-537
7. Managing TBSRTC III thyroid nodules: evaluating repeat FNA, molecular testing, and surgery — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2213294525000742
8. Comparison of thyroid nodule FNA rates recommended by ACR TI-RADS, Kwak TI-RADS and ATA guidelines — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0720048X2200002X
9. Molecular Profiling for Bethesda III to VI Nodules - ScienceDirect.com — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1530891X24000144
10. Long-Term Surveillance for Benign Thyroid Nodules - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1530891X25009814
11. Business of Medicine/Practice Management — aao-hnsfjournals.onlinelibrary.wiley.com — https://aao-hnsfjournals.onlinelibrary.wiley.com/doi/pdf/10.1177/0194599816655337
12. Fate of nondiagnostic thyroid fine needle aspirations - Storozuk - 2024 — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/dc.25386
13. Enhancing diagnostic accuracy of American College... - Ovid — journals.lww.com — https://journals.lww.com/qims/fulltext/2025/02000/enhancing_diagnostic_accuracy_of_american_college.46.aspx
14. [PDF] PHC ENG GUIDE 200 - Extranet Systems — extranet.who.int — https://extranet.who.int/ncdccs/Data/LBN_D1_Final%20EN%20PHC%20Guide%20(September%2025,%202015).pdf
15. Vol 11 Issue 9 p.7-8 |  American Thyroid Association — www.thyroid.org — https://www.thyroid.org/patient-thyroid-information/ct-for-patients/september-2018/vol-11-issue-9-p-7-8
16. Thyroid Health – Molecular testing in thyroid nodules: it is all about risk of malignancy |  American Thyroid Association — www.thyroid.org — https://www.thyroid.org/molecular-testing
17. Vol 11 Issue 9 p.5-6 |  American Thyroid Association — www.thyroid.org — https://www.thyroid.org/patient-thyroid-information/ct-for-patients/september-2018/vol-11-issue-9-p-5-6
18. Vol 18 Issue 7 p.11-12 |  American Thyroid Association — www.thyroid.org — https://www.thyroid.org/patient-thyroid-information/ct-for-patients/july-2025/vol-18-issue-7-p-11-12
19. [PDF] NG230 Thyroid cancer: assessment and management - NICE — www.nice.org.uk — https://www.nice.org.uk/guidance/ng230/evidence/e-efficacy-of-repeat-fine-needle-aspiration-cytology-active-surveillance-or-discharge-pdf-11314085154
20. US-guided Fine-Needle Aspiration of Thyroid Nodules — pubs.rsna.org — https://pubs.rsna.org/doi/abs/10.1148/rg.287085033
21. Recommendations | Thyroid cancer: assessment and management | Guidance | NICE — www.nice.org.uk — https://www.nice.org.uk/guidance/ng230/chapter/Recommendations
22. Thyroid Nodules with Initially Nondiagnostic Cytologic Results — pubs.rsna.org — https://pubs.rsna.org/doi/abs/10.1148/radiol.13122247
23. Management of thyroid nodules with indeterminate fine-needle aspiration cytology: histogram analysis of greyscale sonograms and molecular assay of residual tissue from fine-needle aspiration biopsies - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC9459511
24. [PDF] Thyroid cancer: assessment and management - NCBI — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK589390/pdf/Bookshelf_NBK589390.pdf

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.